This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. To investigate the role of PROG in the regulation of BCRP expression, two constructs encoding full-length BCRP driven by either an endogenous PRE promoter or a constitutive CMV promoter, were transfected into T47D cells that express the progesterone receptor (PR) or into PR-negative MDA-MB-231 cells. Results: After treatment with PROG, qPCR and Western blotting analyses indicated that BCRP on BCRP levels in the PR-negative cells. The effect observed in PR-positive cells was reversed increased by PROG treatment. Conclusion: These results suggest that PROG reverses BCRPmediated MDR by down-regulating BCRP expression in breast cancer cells by affecting transcription from the PRE-containing BCRP promoter. Our studies suggest that breast cancer patients with BCRP-mediated MDR may be successfully treated with PROG.
Introduction
Breast cancer is the most prevalent type of cancer documented in women. Multidrug resistance (MDR) is the greatest obstacle preventing effective chemotherapy treatment in these patients. One outcome of MDR involves the expulsion of a wide range of structurally and functionally unrelated drugs being pumped out of cancer cells by ATP-binding cassette (ABC) transporter proteins [1] . Breast cancer resistance protein (BCRP) is an ABC transporter presence of adriamycin and vincristine. BCRP is expressed at high levels in cells isolated from various tumors [2] [3] [4] . BCRP mediates resistance to adjuvant chemotherapeutic agents inhibit intracellular accumulation and reduce cytotoxic effects [9] . Although much has been uncovered regarding the molecular roles of BCRP, a better understanding of the mechanisms regulating BCRP expression is necessary to guide development of strategies to reverse MDR in breast cancer patients.
Steroid hormones like estrogen and progesterone (PROG) regulate BCRP expression via receptor-mediated pathways. One such example is that of the estrogen receptor (ER), which regulates BCRP expression in breast cancer cells via ER elements (ERE) in the BCRP promoter. Progesterone receptor (PR) is also a steroid hormone receptor and its expression is tightly regulated by estrogen [10] , as such PR levels should be reduced in ER-negative breast cancer cells. However, this is not the case given that certain ER-negative breast cancer types have high levels of PR expression. Our previous studies in isolated cells revealed that BCRP expression is down-regulated upon treatment with toremifene. Toremifene reverses BCRP-mediated MDR through TOR-ER complexes that bind to the ERE in the BCRP promoter and inhibit the transcription of BCRP [11] . The progesterone response element (PRE), which is a similar regulatory element present in the BCRP [12] . Little is known about the role of this novel element in the BCRP-mediated MDR pathway in breast cancer cells.
In PR transfected PR-or ER-negative breast cancer cells, DNA synthesis and cell proliferation are markedly inhibited by PROG treatment [13] , suggesting that PROG may have a role in cancer growth inhibition. In support of this, megestrol acetate (MA), a synthetic breast cancer, endometrial cancer, and prostate cancer. Treatment of breast cancer cells in vitro with MA reverses resistance to adriamycin and vincristine [14] [15] [16] . However, the underlying mechanisms are not understood.
In this study we over-expressed BCRP in PR-positive T47D and PR-negative MDA-MB-231 breast cancer cells and characterized the role of the PRE in the BCRP promoter in BCRP-mediated MDR. Our results provide new insights into PROG-mediated regulation of BCRP expression in human breast cancers. Total RNA was extracted from cell lines using Trizol reagent (TaKaRa, Kyoto, Japan). cDNA synthesis and qualitative real-time PCR (qPCR) reactions were performed as described previously [17] . The primers used to amplify the human BCRP promoter region were 5'-GCC AGT GAC GGC GAC CAA-3' (sense) and 5'-AGC GCT GAC ACG AAC TTC CTA A-3' (antisense). Primers used to amplify the wild-type human BCRP cDNA were 5'-GCT GCG GCC GCG AAC TGG GTA GGA TTT AGG-3' (sense) and 5'-CCC GCG GCC GCT GAA AGA ACC CAA GAC AT-3' (antisense).
BCRP cDNA was inserted into pEGFP-C1 vector behind a CMV promoter (Invitrogen, Carlsbad, CA, USA). This created the vector we refer to as C-BCRP for expression of BCRP under control of the CMV promoter. ApaI/BamHI digestion was used to construct pEGFP/C-BCRP. To generate the pEGFP/P-BCRP construct, the BCRP and then sub-cloned into pEGFP/C-BCRP with SnaBI/NheI digestion to destroy the CMV promoter. The construct, named P-BCRP, allowed expression of BCRP under control of the wild-type BCRP promoter. All constructs were sequenced.
Cell transfection, stable cell line establishment, and drug treatment
were mixed and incubated for an additional 25 min. Cells were initially seeded in 6-well plates at 1 x 10 6 cells per well. After 12 hrs, cells were washed three times with RPMI-1640 and then the mixture of construct and Lipofectamine was added. Six hours after transfection, the culture medium was changed to complete RPMI-1640 with 10% FBS.
For stable cell line establishment, transfected cells were switched to fresh medium and selected by BCRP were maintained in RPMI-1640 with 10% FBS for at least 24 hrs before PROG treatment. PROG was were incubated for another 48 hrs. Cells were then harvested for mRNA and Western blotting analyses.
Quantitative real-time RT-PCR
Total RNA was isolated from cell lines using Trizol reagent (TaKaRa, Kyoto, Japan) according to ReverTra Ace qPCR RT Kit (TOYOBO, ShangHai, China). The BCRP Green Realtime PCR Master Mix (TOYOBO, ShangHai, China) as previously described [18] . The sense BCRP cDNA were 5'-TGGCTGTCATGGCTTCAGTA-3' and cDNA were 5'-ACCCCCACTGAAAAAGATGA-3' and 5'-ATCTTCAAACCTCCATGATG-3', respectively. The mRNA levels of each gene evaluated were normalized to levels of
(control group). Relative BCRP mRNA levels are expressed as 2 .
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry remove cell debris. The extracted proteins were boiled at 100 °C for 5 min and then fractionated on SDS-MA, USA). After blocking with 5% fat-free milk in TBS at room temperature for 2 hrs, the membrane was washed three times with TBST at room temperature and then incubated with a horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG secondary antibody at 37 °C for 1 hr. Finally, the membranes were visualized using an enhanced chemiluminescence kit (Millipore, Billerica, MA, USA) according to the manufacturer's instruction.
Flow cytometric analysis
trypsinization, cells ( 1×10 6 ) were re-suspended in complete RPMI-1640 with 10% FBS as a control, or 5% CO 2 cytometer (BD Biosciences, San Jose, CA, USA) equipped with a 635 nm red diode laser and 670 nm band
Cytotoxicity assay 4 cells in 0.1 ml RPMI-1640 supplemented with 10% FBS were plated each well of a 96-well plate and maintained at 37 °C for 24 hrs. 10 min. Absorbance at 490 nm was measured using an automatic multi-well spectrophotometer (Bio-Rad, Hercules, CA, USA). The relative drug resistance was determined by comparing the IC 50 (drug concentration causing 50% inhibition of cell growth) with growth inhibition curves.
Statistical analyses
Data analysis was performed with SPSS software version 18.0. Results are presented as means ± SD. Comparisons between groups were made using one-way analysis of variance (ANOVA) followed by Student's paired t P<
Results

Expression of PR by T47D and MDA-MB-231 cells
The expression of PR was detected by immunocytochemistry in the two breast cancer cell lines in this study. Nuclei of T47D cells were positive for PR, and nuclei were negative for PR in MDA-MD-231 cells (Fig. 1) .
PROG treatment decreased BCRP mRNA transcription driven by a PRE-containing promoter
To examine whether PROG regulates BCRP expression in a PRE-dependent manner, we evaluated BCRP mRNA levels in PROG-treated PR-positive T47D cells and PR-negative MDA-MB-231cells that stably express BCRP driven either by a CMV promoter (C-BCRP) or the wild-type promoter containing the PRE sequence (P-PCRP). PROG treatment decreased BCRP mRNA levels in a dose-dependent manner in T47D cells that stably expressed P-BCRP BCRP mRNA in cells in which expression P<0.01). PROG plus RU-486 BCRP mRNA levels in C-BCRP expressing T47D cells (Fig. 2D) . No
PROG treatment inhibited BCRP protein expression in PR-positive cells
To further evaluate the effect of PROG on exogenous BCRP protein expression, we treated T47D cells expressing either P-BCRP or C-BCRP with various concentrations of PROG P-BCRP-expressing cells, PROG treatment inhibited BCRP expression in a dose-dependent manner (P<0.01) (Fig. 3A) . In cells containing the BCRP gene driven by the CMV promoter,
P<0.01).
In T47D/C-BCRP cells, both PROG alone 
hrs (C and D). T47D cells expressing (C) P-BCRP or (D) C-BCRP were cultured in the presence or ab-
and the relative BCRP mRNA levels were determined BCRP levels were normalized to levels of . Data were from three independent experiments.
in T47D/Pthe sensitivity of T47D/C-BCRP cells to mitoxantrone increased ~24 fold (P<0.01). The sensitivity of T47D/P-BCRP cells was ~25 fold higher than that of the control cells (P<0.01). After treatment with PROG, the sensitivity was ~5 fold higher than that of the control cells, Value of RR (short for relative drug resistance) of the T47D cells was set as 1. Results are represented as mean ± SD from at least triplicate independent experiments. **P < 0.01 compared with T47D, P < 0.01 compared with T47D/P-BCRP, T47D/C-BCRP+PROG and T47D/C-BCRP. Discussion over-expressed in placental syncytiotrophoblasts, canalicular membranes of the liver, small intestine epithelium, endothelial cells of microvessels, and mammary epithelial cells. The localization of BCRP in normal tissues suggests that it plays a protective role [24, 25] . BCRP variety of chemotherapeutic agents including mitoxantrone, topotecan, and anthracyclines [26, 27] . Nuclear receptors, especially ER, are important determinants of BCRP expression levels in tumor cells. Imai et al. reported that both estrogens and anti-estrogens restrain BCRPmediated drug resistance. Furthermore, they found that physiological levels of estradiol (E 2 ) 2 regulates the level of BCRP mRNA at the transcriptional level [11] . We found that down-regulation of BCRP gene expression and the reversal of multi-drug TOR-ER complex binds to the ERE in the BCRP promoter and associates with components of the transcription machinery to inhibit transcription activation of BCRP [31] . However, the effect of PR on the regulation of BCRP in breast cancer was not clear.
PR may be regulated by ER, and the presence of PR suggests that ER is not only present but also functional in various types of cancer cells [32] . However, about 10% of primary breast cancers are negative for ER but positive for PR. A recent retrospective analysis of the breast cancer patients treated with tamoxifen or with aromatase inhibitors showed that patients with ER [33, 34] . Thus, PR may have ER-independent functions in breast cancer.
BCRP promoter is similar to the ERE [12, 35] , suggesting that the response element might interact with both ER and PR. Reports on the role of PROG in the treatment of breast cancer are controversial. Synthetic progestin regulates transcription differently in normal cells than in breast cancer cells [36] . Although progestin agents appear to stimulate tumor growth under certain conditions [37] , one study found that the use of progesterone alone increases breast cancer risk in women [38] . Li et al. demonstrated that nomegestrol acetate reverses multi-drug resistance in MCF-7/ADR cells by down-regulating both mRNA and proteins levels of P-gp and markedly increases intracellular adriamycin accumulation [39] . However, the role of PR in BCRP expression in breast cancer remains unknown.
We have reported that the PROG/PR complex binds to the PRE in the BCRP promoter and regulates BCRP expression in PR-positive breast cancer cells [40] . In the current study, we sought to clarify the molecular mechanisms by which PR regulates BCRP expression. We constructed plasmids containing BCRP cDNA driven by the wild-type PRE promoter (P-BCRP) or a constitutive CMV promoter (C-BCRP). We then established T47D (PR + ) and MDA-MB-231 (PR -) cells that stably expressed the two genes and investigated the regulation of PROG on BCRP-mediated drug resistance [41] . We observed that PROG negatively regulated exogenous BCRP gene expression at the transcriptional level in T47D/P-BCRP cells at typical concentrations of circulating hormones. Furthermore, the suppression of PROG was abolished by the addition of RU-486 at a dose equal to a ten-fold molar ratio excess to that of PROG. In T47D/C-BCRP cells, in which BCRP is constitutively expressed, PROG had little [42] . In this article, we only addressed classical nPRs and not the rapid activation of intracellular signaling pathways mediated by extra-nuclear PR. Further research will be necessary to clarify the contributions of the three types of receptors in the regulation of BCRP expression. In contrast to our results in T47D cells, Wang et al. reported that PROG up-regulated BCRP expression in BeWo cells [43] . In our study, BCRP expression was driven by the endogenous promoter containing a consensus PRE. In contrast, a Harvey retroviral long terminal repeat promoter drove expression in BeWo cells in the study by Wang et al. Although this difference in promoter may result in the difference in expression observed in the two cell types, the regulation of BCRP expression and function by PROG may occur through different mechanisms in different cells types. For example, further studies are required to explore whether the two PR isoforms, PR-A and PR-B, have different functions.
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